Candel Therapeutics, Inc. (NASDAQ:CADL) Receives $18.00 Consensus Target Price from Analysts

Posted by Francis Steltz on Jun 6th, 2026

Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.00.

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group restated a “buy” rating and set a $25.00 target price on shares of Candel Therapeutics in a research report on Friday, March 13th. Zacks Research upgraded shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Cantor Fitzgerald assumed coverage on shares of Candel Therapeutics in a research report on Monday, April 20th. They set an “overweight” rating for the company. Wall Street Zen upgraded shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Monday, April 20th.

Get Our Latest Report on Candel Therapeutics

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC increased its holdings in Candel Therapeutics by 4.9% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 42,517 shares of the company’s stock valued at $240,000 after buying an additional 2,000 shares in the last quarter. Invesco Ltd. increased its holdings in Candel Therapeutics by 29.0% in the fourth quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock valued at $85,000 after buying an additional 3,380 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Candel Therapeutics by 12.6% in the first quarter. Janney Montgomery Scott LLC now owns 30,472 shares of the company’s stock valued at $149,000 after buying an additional 3,400 shares in the last quarter. MetLife Investment Management LLC increased its holdings in Candel Therapeutics by 25.5% in the fourth quarter. MetLife Investment Management LLC now owns 19,443 shares of the company’s stock valued at $110,000 after buying an additional 3,955 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after buying an additional 4,439 shares in the last quarter. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Trading Down 8.2%

NASDAQ CADL opened at $8.51 on Monday. The company has a market capitalization of $623.53 million, a PE ratio of -8.68 and a beta of -0.49. The company has a fifty day moving average of $6.88 and a 200 day moving average of $5.94. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $9.57. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.16. Research analysts forecast that Candel Therapeutics will post -0.97 earnings per share for the current year.

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.